Secondary Logo

Institutional members access full text with Ovid®

Pneumocystis pneumonia: an opportunistic infection occurring in patients with severe alcoholic hepatitis

Faria, Luciana Costaa b c; Ichai, Philippea b c; Saliba, Faouzia b c; Benhamida, Soniaa; Antoun, Fadia; Castaing, Denisa b c; Samuel, Didiera b c

European Journal of Gastroenterology & Hepatology: January 2008 - Volume 20 - Issue 1 - p 26-28
doi: 10.1097/MEG.0b013e3282f16a10
Original Articles: Hepatitis and Ethanol Abuse

Background Pneumocystis pneumonia usually occurs in immunosuppressed individuals, generally those with underlying T-lymphocyte disorders. Patients with alcoholic liver disease display immune responses consistent with those observed in immunocompromised individuals and alcohol is a potent immunosuppressor. Long-term corticotherapy represents a risk for Pneumocystis pneumonia.

Patients and methods From 1998 to 2006, seven patients hospitalized in our Liver Intensive Care Unit for severe alcoholic hepatitis had a diagnosis of Pneumocystis pneumonia. All had liver biopsies revealing histologic evidence of alcoholic hepatitis. The diagnosis of pneumocystosis was established by the detection in the bronchoalveolar lavage of the characteristic pathogen, with Giemsa staining or immunofluorescence assay, in addition to the presence of clinical and radiological signs of pneumopathy.

Results All seven patients had a Maddrey score higher than 32. Six patients received corticotherapy for alcoholic hepatitis treatment before the diagnosis of Pneumocystis pneumonia. All patients developed acute respiratory distress syndrome and needed mechanical ventilation. In three patients, the test for cytomegalovirus was also positive in the bronchoalveolar lavage. All seven patients died in spite of receiving appropriate treatment.

Conclusion Chronic alcoholism and alcoholic liver disease are both associated with an important degree of immunosuppression. Corticotherapy, even for a short period, may aggravate this immunodeficiency and predispose these patients to severe opportunistic infections.

aAP-HP Hôpital Paul Brousse, Hepatobiliary Center, Villejuif

bUniv Paris-Sud, UMR-S 785

cInserm, Unité 785, Villejuif, F-94804, France

Correspondence to Professor Didier Samuel, MD, Centre Hepato-Biliaire, Hopital Paul Brousse, Villejuif 94800, France

Tel: +33 1 45593411; fax: +33 1 45593857;


Received 7 February 2007 Accepted 17 July 2007

© 2008 Lippincott Williams & Wilkins, Inc.